Background: To determine whether the change in tumor diameters at the first follow-up computed tomography (CT) examination after baseline examination (first change) correlates with outcome in patients with metastatic colorectal cancer (mCRC) treated with combination chemotherapy.
introduction
In spite of remarkable progress in understanding molecular mechanisms in cancer cells, treatment response evaluation of solid tumors relies on changes in size assessed by imaging, mainly computed tomography (CT). According to the World Health Organization (WHO) response evaluation criteria, the RECIST and RECIST 1.1, the change of lesion size is quantified, categorized, and used to indicate treatment efficacy [1] [2] [3] . The criteria were originally developed to evaluate the efficacy of chemotherapy in metastatic disease but have also been used in the evaluation of the primary tumor and applied to many antitumor treatments, including novel targeted agents. Since the WHO criteria were published in 1979, a decrease of >50% and an increase of >25% in the product of the largest diameter (LD) and the perpendicular tumor diameter have been used as cut-off values in recording an objective response (OR) [4] . When the new RECIST criteria were determined, these cut-off values were used after a mathematical conversion from bi-to unidimensional measurements. Additionally, the cut-off value for progression went from a 40% increase in volume using WHO criteria to a 73% increase in volume using RECIST [5] . There was no biological or radiological background to these original thresholds; instead, it was a way to minimize errors in reporting changes in size of spheres under foam rubber [4] . Imaging techniques have evolved and more accurate estimations can be obtained.
The value of this 'OR evaluation' as a surrogate indicator for different treatments on patient-related outcomes has been debated. Relevant patient-related outcomes include quality of life, overall survival (OS), and lately progression-free survival (PFS) [6, 7] . Studies of different tumor types, particularly colorectal cancer (CRC), have failed to show a strong correlation between an OR and prolonged survival [7] [8] [9] . Patients who respond well to treatment have better patient characteristics at baseline. Thus, these patients are likely to have a longer survival than those who do not respond and are guaranteed a minimum time to the response evaluation. After compensating for these biases, meta-analyses of prospective trials revealed statistically significant correlations between OR and OS in metastatic CRC (mCRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy [8, 9] . Moreover, a survival benefit has been shown not only for patients who had a complete response (CR) or a partial response (PR) but also for those who maintained stable disease (SD) for at least 4 months; the latter patients did not satisfy the WHO criteria requirements for PR [7] . RECIST's thresholds were also recently questioned in an mCRC trial including the epidermal growth factor receptor inhibitor cetuximab [10, 11] .
Few physicians and researchers have questioned the relevance of these thresholds for response classification using conventional combination chemotherapy. Instead, the value of functional imaging for early response prediction has been the focus, with contradictory results [12] [13] [14] [15] . Furthermore, the relevance of early changes in size has not been well explored. In a modeling study, based on phase II data using fluoropyrimidines only, and applied to a subsequent phase III study, early changes in size were prognostic for OS [16] .
The purpose of this study was to determine whether the change in tumor size at the first follow-up CT examination compared with baseline (first change) correlates with outcome in patients with mCRC treated with combination chemotherapy. The change in tumor size from the first to the second response evaluation (second change) was also recorded to better understand whether continued changes also could predict outcome.
patients and methods

patients
The patients were enrolled in the multicenter randomized phase III Nordic VI trial (N = 567) comparing irinotecan with either the Nordic bolus 5-FU and folinic acid schedule (FLIRI) or the de Gramont schedule (Lv5FU2-IRI) [17] . Both FLIRI and Lv5FU2-IRI treatments were repeated every 2 weeks until disease progression or unacceptable toxicity. CT scans of the chest and the abdomen were obtained at baseline within 3 weeks before randomization and repeated after every four cycles (every 8 weeks). Response evaluation was conducted according to the RECIST 1.0; CR means disappearance of all signs of tumor; PR means at least a 30% decrease in the sum of the LDs of the target lesions; progressive disease (PD) means at least a 20% increase in the sum of the LDs of the target lesions or the appearance of new lesions or unequivocal progression of nontarget lesions; and SD means neither PR nor PD. There was no significant difference in PFS, median 9 months (P = 0.4), or OS, median 19 months (P = 0.4), in the two groups; however, response rates were more common using Lv5FU2-IRI compared with FLIRI (49% versus 35%, P = 0.001) [17] .
The Nordic VI study was chosen for practical reasons and that modern chemotherapy regimens were used. The study protocol was approved by the regional ethical committees.
definition of first change, second change, SD2, and SD4
The first change in tumor size (first change) was calculated as the ratio of the sum of the LDs of target lesions at the baseline study (baseline sum) and the sum of the LDs of the same target lesions at the first follow-up CT (first sum). first change = ½ðfirst sumÞ2 ðbaseline sumÞ=ðbaseline sumÞ Likewise, the second change was calculated by the ratio of the difference of the sum of the LDs at the first and second follow-up studies.
If a patient maintained SD for 2 but not 4 months, the patient was subclassified as SD2. A patient who maintained SD for at least 4 months was subclassified as SD4 [7] . The original definition of response and the size estimations recorded in the case record forms (CRFs) were used.
statistical design
PFS and OS were the time from randomization to the date of any progression or death. The primary end points of this study were the correlations between first change and OS and PFS. Additional end points were to examine the relevance on OS and PFS of the second follow-up study. The landmark method to compensate for longer guarantee time for responders was applied for first and second change and OR according to RECIST, respectively, in the PFS and OS analyses [7, 8] . The guarantee-time period for first change was 60 days, and for second change and RECIST, it was 120 days. Patients alive or progression free at the last follow-up were censored.
The relations between the first change value and PFS and OS were first explored using the change as a continuous variable. For illustrative purposes, to be more relevant in the clinics and comparable with the present evaluation criteria, patients were grouped according to the first change value. The increase ranges were ‡20%, ‡10 to <20, and >0 to <10. The decrease ranges were 0 to <10%, ‡10 to <20%, ‡20 to <30%, ‡30 to <40%, ‡40 to <50%, and ‡50%. In addition, a group where either new lesion(s) or progression of nontarget lesion(s) appeared was also included. Chi-square test or Fisher's exact test was applied to compare two independent groups. The Cox proportional hazards multiple regression model, including first change values, age, number of metastases, and treatment arm, was used to define prognostic variables and to estimate hazard ratios and 95% confidence intervals (CIs). The durations of PFS and OS were estimated by the Kaplan-Meier method. The log-rank test was used for comparison between groups.
To assess the reliability of first change values, an external reviewer (AS) independently selected tumors and measured the baseline sum and the first sum for 86 randomly selected patients. The aim was to reassess 100 patients (20%), but the CT studies could not be traced in 14 patients. The reviewer had no information about the original radiological response assessments or patient outcomes. The intraclass correlation coefficient (ICC) was estimated. The ICC ranges from 0.00 to 1.00, with 1.00 representing better reliability. The repeatability coefficient was also estimated based on ICC analysis.
A value of P < 0.05 was considered statistically significant. Statistical computations were carried out with StatXact 4 (CYTEL Software Corp., Cambridge, MA) and STATISTICA version 9 (StatSoft Inc., Tulsa, OK).
results patient characteristics
A total of 506 patients were eligible for the first change analyses. The reason for ineligibility was a lack of measurement either at baseline or at the first follow-up examination (n = 61). Most of these patients had stopped treatment early because of severe toxicity or disease progression. Fifty-eight patients had PD at the first follow-up examination. Sixteen patients were not eligible for the second change analyses because of no measurement at the second follow-up. A total of 432 patients were thus eligible for the second change analyses. Patient characteristics are shown in Table 1 . the randomization groups. The number of patients who showed a first change of at least a 10% decrease was 143 (57%) of 251 randomized to receive FLIRI and 160 (63%) of 255 randomized to receive Lv5FU2-IRI (P = 0.20). Nevertheless, response rate was discordant and higher in Lv5FU2-IRI compared with FLIRI (53% versus 38%, P = 0.0009) as shown in the original study including all 567 patients [17] .
relationship between first change and overall survival
The first change used as a continuous variable correlated strongly to OS (Table 2) . When categorized into groups differing by 10 percentage points, a decrease between 10% and 20% and between 20% and 30%, both of which would have been regarded as SD according to RECIST, significantly predicted improved OS relative to an increase of <10%. A decrease in size by ‡50% was the most positive prognostic factor for OS. In the absence of a new lesion or unequivocal progression of nontarget lesions, even an increase of ‡20%, considered as PD by RECIST, was not statistically significantly associated with impaired OS versus an increase of <10%.
Appearance of a new lesion or progression of nontarget lesion(s), irrespective of the change in diameters in the target lesions, was the most negative prognostic factor for OS (Table 2) . Based on the results of the Cox regression model, patients were regrouped into four groups: (i) having new lesion/ unequivocal nontarget lesion progression, (ii) any increase to <10% decrease, (iii) ‡10% to <50% decrease, or (iv) a decrease of ‡50%. We considered this subgrouping as clinically more relevant than to subgroup according to quartiles. The difference in OS was statistically significant among these four groups (landmark method, log-rank test, P < 0.00001) ( Figure 1A) . The four RECIST categories could similarly discriminate OS ( Figure 1B) . The proportion who survived longer than median OS in the Nordic VI trial (19 months) was 4% in the first group, 37% in the second group, 60% in the third group, and 80% in the fourth group. The corresponding numbers according to RECIST were 5% for PD, 33% for SD, 59% for PR, and 100% for CR. Among the 23 CR patients, 4 (17%) achieved CR after resection of metastases.
relationship between first change and PFS Similar to OS, the PFS increased as the first change value decreased (Table 3) . Even a ‡10% to <30% decrease (SD according to RECIST) was associated with improved PFS versus an increase <10% at a statistically significant level. A decrease in size by ‡50% was again the most significant positive prognostic factor of PFS (Table 3) . The numbers of SD4 and SD2 were given for those who underwent the second follow-up after 4 months (n = 432). CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
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Patients were regrouped according to the first change values: (i) having new lesion/nontarget lesion progression, (ii) any increase to a <10% decrease, (iii) ‡10% to <50% decrease, or (iv) ‡50% decrease. The difference in PFS among these four groups was statistically significant (landmark method, log-rank test, P < 0.00001) ( Figure 1C ). The same was seen for the RECIST categories ( Figure 1D ). The percentages of those who had a longer PFS than median PFS in the Nordic VI trial (9 months) were 0% in the first group, 23% in the second group, 41% in the third group, and 61% in the fourth group. The corresponding figures according to RECIST were 0% for PD, 22% for SD, 31% for PR, and 82% for CR.
reliability of first change values
The ICC was 0.78 (95% CI 0.68-0.85), with a repeatability coefficient of 0.51. The reobtained first change values also correlated with PFS and OS (P = 0.00065 and 0.0134, respectively).
the second follow-up examination
At the first evaluation, 283 patients were assessed as SD. Of these, 43 patients (15%) had disease progression before 4 months (designated SD2). The reason for progression was a new lesion or progression of the nontarget lesion(s) for 28 (56%) of the 50 patients. Patients with SD4 had significantly longer OS compared with those with SD2 (median 497 versus 358 days, log-rank test, P = 0.00742). The mean first change values for SD2 and SD4 were 20.12 (standard deviation 0.19) and 20.09 (standard deviation 0.13), respectively, without any statistically significant difference (P = 0.13). However, the chance of being SD4 was significantly higher if a patient's first change showed a decrease of ‡10% (P = 0.00658) (Figure 2) . Similar to the strong predictive ability of PFS and OS by the first change from baseline to 2 months, the appearance of a new lesion or progression of nontarget lesion(s) at the second change was the single significant negative variable and a decrease by ‡50% was the single significant positive variable for both PFS and OS (Table 4) . For other variables, any increase to a decrease of <50% did not achieve a level of statistical significance different from no change. chemotherapy for mCRC correlates with patient prognosis in terms of PFS and OS. This has never been shown before besides for a modeling study to support end of phase II decision and design for phase III studies [16] . It cannot be established whether the first change is a prognostic factor only or whether a decrease in tumor size at this assessment predicts treatment benefit [18] . Still, the comparison of cytotoxic treatments in a trial can be achieved more rapidly by the first change approach than to wait for maximal response evaluation using RECIST. Further prognostic information is obtained from changes after the first 2 months, but this information is less useful than the first change because only marked changes (new lesions/progression of nontarget lesions and a >50% decrease) are informative. Although response rate is a meaningful end point in testing new treatments for mCRC and has been used for decades, the relations between response rates and survival are limited [9, 19] . These results question the cut-off values currently used to evaluate tumor response. The cut-off values used by RECIST between PD and SD on the one hand and between SD and PR on the other do not seem to be optimally chosen. Interestingly, the cut-off value for improved outcome found first change of a decrease of ‡10%, which is the same as Choi's criteria for gastrointestinal stromal tumor (GIST) treated with imatinib [20] and mCRC treated with cetuximab [10, 11] . An explanation for the relevance of only a 10% decrease might be related to the number of eradicated cells by the treatment. In a spherical tumor (a tumor with a diameter of, for instance, 1 cm consists of 10 9 cells [21, 22] ), a 10% shrinkage indicates almost 30% cell kill. The chosen cut-off values should be reappraised from a clinical standpoint [19] and not only look upon measurement errors [2, 4, [23] [24] [25] [26] [27] . In this study, the repeatability of the investigator determined tumor measurement was reasonably high, and well in line with other studies where ORs have been centrally assessed [26] . The consistency of measurement could be improved if exactly the same lesions are measured or automated measuring tools are adopted [25] [26] [27] . Although only a subgroup of the patients was reassessed, the first change provided the same prognostic information as the original assessment.
In the group of patients with PD according to RECIST, our study found a marked difference in prognosis between patients with or without a new lesion or unequivocal progression of nontarget lesion(s). To our knowledge, this has not been reported before, nor incorporated in the simulation model [16] . If true, the appearance of new lesions or progression of nontarget lesions could mean that the tumor disease is biologically more aggressive than when the progression is only due to an increase in the size of target lesions. A new lesion may mean an increase from undetectable sub-centimeter to 1 cm, and this should not immediately indicate more aggressiveness A limitation of the study is that we retrospectively studied one time point for the follow-up study (8 weeks), which was defined by trial protocol. We cannot know if this time point is optimal for measuring first change. Six weeks after initiation of chemotherapy with cetuximab for mCRC [11] , 7 weeks after initiation of capecitabine or 5-FU for mCRC [16] , or 8 weeks after initiation of imatinib therapy for GIST [20] have been used also. Many researchers have suggested that it might be better to monitor treatment effects by PET, e.g. after one or two cycles of treatment [12] , but others have not found that this is sufficiently discriminative in mCRC studies [14, 15] .
In conclusion, first change in tumor size is a potent imaging surrogate of PFS and OS in mCRC. Even smaller changes than RECIST requires for a PR are associated with survival prolongation. The appearance of new lesions or unequivocal progression of nontarget lesions indicates particularly poor prognosis. A retrospective analysis of one study cannot change the widely adopted RECIST criteria. If the results can be confirmed in other, preferably prospective studies using other regimen including biological agents and in other tumor types, future response evaluation criteria should be better adapted to reflect important outcomes. The group that showed no change to up to a 10% increase at the second follow-up was referred to as a reference group (HR = 1.0). Other variables, from any increase to decrease <50%, were not significantly different from 1.0. New, nontarget: appearance of new lesion or progression of nontarget lesion. 
